全文获取类型
收费全文 | 3914篇 |
免费 | 256篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 149篇 |
妇产科学 | 199篇 |
基础医学 | 467篇 |
口腔科学 | 97篇 |
临床医学 | 381篇 |
内科学 | 764篇 |
皮肤病学 | 61篇 |
神经病学 | 356篇 |
特种医学 | 147篇 |
外科学 | 664篇 |
综合类 | 22篇 |
一般理论 | 3篇 |
预防医学 | 286篇 |
眼科学 | 70篇 |
药学 | 215篇 |
中国医学 | 2篇 |
肿瘤学 | 247篇 |
出版年
2023年 | 21篇 |
2022年 | 37篇 |
2021年 | 86篇 |
2020年 | 62篇 |
2019年 | 96篇 |
2018年 | 109篇 |
2017年 | 92篇 |
2016年 | 100篇 |
2015年 | 99篇 |
2014年 | 129篇 |
2013年 | 202篇 |
2012年 | 256篇 |
2011年 | 301篇 |
2010年 | 189篇 |
2009年 | 148篇 |
2008年 | 219篇 |
2007年 | 219篇 |
2006年 | 227篇 |
2005年 | 230篇 |
2004年 | 197篇 |
2003年 | 179篇 |
2002年 | 169篇 |
2001年 | 75篇 |
2000年 | 71篇 |
1999年 | 62篇 |
1998年 | 35篇 |
1997年 | 35篇 |
1996年 | 22篇 |
1995年 | 17篇 |
1994年 | 26篇 |
1993年 | 24篇 |
1992年 | 33篇 |
1991年 | 35篇 |
1990年 | 28篇 |
1989年 | 34篇 |
1988年 | 28篇 |
1987年 | 28篇 |
1986年 | 21篇 |
1985年 | 38篇 |
1984年 | 29篇 |
1983年 | 17篇 |
1982年 | 22篇 |
1981年 | 13篇 |
1979年 | 9篇 |
1976年 | 10篇 |
1975年 | 9篇 |
1973年 | 8篇 |
1972年 | 8篇 |
1970年 | 8篇 |
1966年 | 7篇 |
排序方式: 共有4182条查询结果,搜索用时 15 毫秒
141.
142.
143.
144.
Prevalence of type 1 Gaucher disease in the United States 总被引:1,自引:0,他引:1
Weinreb NJ Andersson HC Banikazemi M Barranger J Beutler E Charrow J Grabowski GA Hollak CE Kaplan P Mankin H Mistry PK Rosenbloom BE Vom Dahl S Zimran A 《Archives of internal medicine》2008,168(3):326-7; author reply 327-8
145.
Ari K. Leppäniemi M.D. Hannu O. Savolainen M.D. Jarmo A. Salo M.D. Pertti T. Aarnio M.D. F.I.C.A. 《The International journal of angiology》1995,4(4):177-181
In a review of more than 1000 patients with operatively managed abdominal trauma, eight patients with injuries to the proximal parts of the superior mesenteric artery or vein were identified: three with either a superior mesenteric artery or vein injury and two with combined superior mesenteric vessel injuries. All patients were in shock on arrival, and had associated abdominal injuries. All six patients with solitary superior mesenteric artery or vein injuries underwent lateral suture repair of the injured vessel with good results. The combined injuries of both of the superior mesenteric vessels required more complex types of vascular repairs: an interposition saphenous vein graft for the arterial injury and ligation of the vein in one patient who later died of bowel necrosis, and an end-to-end arterial repair and lateral venorrhaphy in the other who had a viable bowel at a second look operation. The overall mortality rate was 13%. The various management options and guidelines for injuries to the proximal parts of the superior mesenteric vessels are discussed. 相似文献
146.
Eric Edeline Tamara Ben Ari L. Asbjrn Vllestad Ian J. Winfield Janice M. Fletcher J. Ben James Nils C. Stenseth 《Proceedings of the National Academy of Sciences of the United States of America》2008,105(50):19792-19796
Selection can alter predator-prey interactions. However, whether and how complex food-webs respond to selection remain largely unknown. We show in the field that antagonistic selection from predators and pathogens on prey body-size can be a primary driver of food-web functioning. In Windermere, U.K., pike (Esox lucius, the predator) selected against small perch (Perca fluviatilis, the prey), while a perch-specific pathogen selected against large perch. The strongest selective force drove perch trait change and ultimately determined the structure of trophic interactions. Before 1976, the strength of pike-induced selection overrode the strength of pathogen-induced selection and drove a change to larger, faster growing perch. Predation-driven increase in the proportion of large, infection-vulnerable perch presumably favored the pathogen since a peak in the predation pressure in 1976 coincided with pathogen expansion and a massive perch kill. After 1976, the strength of pathogen-induced selection overrode the strength of predator-induced selection and drove a rapid change to smaller, slower growing perch. These changes made perch easier prey for pike and weaker competitors against juvenile pike, ultimately increasing juvenile pike survival and total pike numbers. Therefore, although predators and pathogens exploited the same prey in Windermere, they did not operate competitively but synergistically by driving rapid prey trait change in opposite directions. Our study empirically demonstrates that a consideration of the relative strengths and directions of multiple selective pressures is needed to fully understand community functioning in nature. 相似文献
147.
Lucey MR Silverman BL Illeperuma A O'Brien CP 《Alcoholism, clinical and experimental research》2008,32(3):498-504
Background: Hepatoxicity has been reported with oral naltrexone. Hepatic safety data were examined from a 6-month study evaluating the efficacy and safety of a now available extended-release formulation of naltrexone (XR-NTX) in patients with alcohol dependence.
Methods: In all, 624 patients (68% male; median age of 44 years) were randomly assigned to XR-NTX 380 mg ( n = 205), XR-NTX 190 mg ( n = 210), or placebo ( n = 209).
Results: There were no significant differences in alanine aminotrasferase, aspartate aminotransferase, or bilirubin levels between the study groups at study initiation or at subsequent assessments. Gamma-glutamyltransferase in the XR-NTX 380 mg group was lower compared with placebo at weeks 4, 8, 12, and 20. Both high (>3 times the upper limit of normal) liver chemistry tests (LCTs) and hepatic-related adverse events were infrequent in all study groups. In patients who were drinking heavily throughout the study, obese subjects, or those taking nonsteroidal anti-inflammatory drugs, there was no increase in frequency of high LCTs or hepatic-related adverse events in patients receiving XR-NTX (either dose) compared with placebo.
Conclusion: Extended-release formulation of naltrexone does not appear to be hepatotoxic when taken at the recommended clinical doses in actively drinking alcohol-dependent patients. 相似文献
Methods: In all, 624 patients (68% male; median age of 44 years) were randomly assigned to XR-NTX 380 mg ( n = 205), XR-NTX 190 mg ( n = 210), or placebo ( n = 209).
Results: There were no significant differences in alanine aminotrasferase, aspartate aminotransferase, or bilirubin levels between the study groups at study initiation or at subsequent assessments. Gamma-glutamyltransferase in the XR-NTX 380 mg group was lower compared with placebo at weeks 4, 8, 12, and 20. Both high (>3 times the upper limit of normal) liver chemistry tests (LCTs) and hepatic-related adverse events were infrequent in all study groups. In patients who were drinking heavily throughout the study, obese subjects, or those taking nonsteroidal anti-inflammatory drugs, there was no increase in frequency of high LCTs or hepatic-related adverse events in patients receiving XR-NTX (either dose) compared with placebo.
Conclusion: Extended-release formulation of naltrexone does not appear to be hepatotoxic when taken at the recommended clinical doses in actively drinking alcohol-dependent patients. 相似文献
148.
149.
150.
Effects of α tocopherol and β carotene supplements on symptoms, progression, and prognosis of angina pectoris
下载免费PDF全文
![点击此处可从《Heart (British Cardiac Society)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J Rapola J Virtamo S Ripatti J Haukka J Huttunen D Albanes P Taylor O Heinonen 《Heart (British Cardiac Society)》1998,79(5):454-458
Objective—To evaluate the effects of α tocopherol and β carotene supplements on recurrence and progression of angina symptoms, and incidence of major coronary events in men with angina pectoris.
Design—Placebo controlled clinical trial.
Setting—The Finnish α tocopherol β carotene cancer prevention study primarily undertaken to examine the effects of α tocopherol and β carotene on cancer.
Subjects—Male smokers aged 50-69 years who had angina pectoris in the Rose chest pain questionnaire at baseline (n = 1795).
Interventions—α tocopherol (vitamin E) 50 mg/day, β carotene 20 mg/day or both, or placebo in 2 × 2 factorial design.
Main outcome measures—Recurrence of angina pectoris at annual follow up visits when the questionnaire was readministered; progression from mild to severe angina; incidence of major coronary events (non-fatal myocardial infarction and fatal coronary heart disease).
Results—There were 2513 recurrences of angina pectoris during follow up (median 4 years). Compared to placebo, the odds ratios for recurrence in the active treatment groups were: α tocopherol only 1.06 (95% confidence interval (CI) 0.85 to 1.33), α tocopherol and β carotene 1.02 (0.82 to 1.27), β carotene only 1.06 (0.84 to 1.33). There were no significant differences in progression to severe angina among the groups given supplements or placebo. Altogether 314 major coronary events were observed during follow up (median 5.5 years) and the risk for them did not differ significantly among the groups given supplements or placebo.
Conclusions—There was no evidence of beneficial effects for α tocopherol or β carotene supplements in male smokers with angina pectoris, indicating no basis for therapeutic or preventive use of these agents in such patients.
Keywords: antioxidants; angina pectoris; prevention; vitamin supplements 相似文献
Design—Placebo controlled clinical trial.
Setting—The Finnish α tocopherol β carotene cancer prevention study primarily undertaken to examine the effects of α tocopherol and β carotene on cancer.
Subjects—Male smokers aged 50-69 years who had angina pectoris in the Rose chest pain questionnaire at baseline (n = 1795).
Interventions—α tocopherol (vitamin E) 50 mg/day, β carotene 20 mg/day or both, or placebo in 2 × 2 factorial design.
Main outcome measures—Recurrence of angina pectoris at annual follow up visits when the questionnaire was readministered; progression from mild to severe angina; incidence of major coronary events (non-fatal myocardial infarction and fatal coronary heart disease).
Results—There were 2513 recurrences of angina pectoris during follow up (median 4 years). Compared to placebo, the odds ratios for recurrence in the active treatment groups were: α tocopherol only 1.06 (95% confidence interval (CI) 0.85 to 1.33), α tocopherol and β carotene 1.02 (0.82 to 1.27), β carotene only 1.06 (0.84 to 1.33). There were no significant differences in progression to severe angina among the groups given supplements or placebo. Altogether 314 major coronary events were observed during follow up (median 5.5 years) and the risk for them did not differ significantly among the groups given supplements or placebo.
Conclusions—There was no evidence of beneficial effects for α tocopherol or β carotene supplements in male smokers with angina pectoris, indicating no basis for therapeutic or preventive use of these agents in such patients.
Keywords: antioxidants; angina pectoris; prevention; vitamin supplements 相似文献